查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924745

沙庫巴曲Valsartan鈉錠市場按產品類型、規格、劑型、分銷管道和最終用戶分類－2026年至2032年全球預測

Sacubitril Valsartan Sodium Tablets Market by Product Type, Strength, Dosage Form, Distribution Channel, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年沙庫巴曲Valsartan鈉錠市場價值為 102.2 億美元，預計到 2026 年將成長至 109.8 億美元，預計到 2032 年將達到 172.8 億美元，複合年成長率為 7.78%。

主要市場統計數據
基準年 2025 102.2億美元
預計年份：2026年 109.8億美元
預測年份：2032年 172.8億美元
複合年成長率 (%) 7.78%

簡要概述沙庫巴Valsartan鈉錠，包括治療背景、臨床意義以及心血管護理相關人員的策略考量。

沙庫巴曲Valsartan鈉錠在現代心臟衰竭治療中扮演關鍵角色。該藥物結合了腦啡肽酶抑制劑和血管收縮素受體阻斷劑，能夠調節導致發病率和死亡率的疾病路徑。臨床醫生擴大將這種聯合治療作為指南指導的醫療方案的一部分，用於治療合適的患者群體。此療法的應用取決於臨床證據、藥品目錄決策和供應情況的綜合考量。對於行業相關人員，了解臨床應用趨勢、治療定位以及確保患者持續獲得治療的營運因素，對於制定協調一致的策略至關重要。

新興的治療方法、監管和供應趨勢正在重塑沙庫巴Valsartan錠市場格局，並影響其臨床應用和分銷網路。

沙庫巴曲Valsartan鈉錠的治療和商業環境正經歷多重融合的變革，這些變革正在重新定義產品的研發、分銷和報銷方式。真實世界證據產生和電子健康記錄的進步，使得我們能夠更清晰地了解患者在受控臨床試驗之外的治療結果，從而影響藥品目錄的收錄決策和醫療服務提供者的採納。同時，多個司法管轄區的監管機構正在明確核准後風險管理和生產品質方面的要求，鼓勵生產商最佳化其品質系統並提高供應鏈透明度。

評估2025年實施的關稅變動對沙庫巴Valsartan鈉片供應鏈、價格壓力和跨境貿易的累積影響

2025年的關稅調整對包括沙庫巴Valsartan鈉片在內的藥品國際供應鏈產生了複雜的下游影響。進口關稅及相關行政變更正在影響原料採購決策、製造地的經濟效益以及成品供應商的相對競爭力。依賴跨境供應活性成分和成品製劑的製造商被迫重新評估合約條款、避險策略和庫存緩衝，以確保臨床通路的供應不間斷。

透過細分市場獲得更深入的洞察，揭示分銷管道、最終用戶、產品類型、劑型和劑量對產品可及性和臨床應用的影響。

市場區隔有助於深入了解沙庫巴Valsartan鈉錠的使用管道和獲取動態，而詳盡的觀點對於制定精準策略至關重要。檢驗分銷管道揭示了營運現實的差異。醫院藥局在政府或私立醫院的採購框架內運作，這些框架強調處方集委員會和機構合約。線上藥局引入了直接面向患者的配送動態，但需要考慮監管合規性和低溫運輸。同時，零售藥局既包括採用標準化採購的連鎖藥局，也包括依賴本地相關性和庫存即時競爭的獨立門市。

區域差異和商業性趨勢（美洲、歐洲、中東和非洲、亞太地區）會影響製造、監管和分銷策略。

地理差異會影響沙庫巴Valsartan鈉錠的監管合規、製造地選擇和商業部署，而區域觀點有助於確定產能投資的優先順序。在美洲，整合的醫療體系、先進的支付模式和完善的分銷網路為基於價值的合約和廣泛的臨床應用創造了機遇，同時也要求嚴格的藥物監測和與報銷文件的協調一致。在歐洲、中東和非洲營運的相關人員面臨著監管時間表、定價談判框架和採購實踐方面的差異，因此需要製定適應性強的打入市場策略和區域性的監管支持。

領先的開發商和製造商的企業定位和競爭策略將塑造該治療領域的創新軌跡和夥伴關係機會。

該治療領域的企業正透過差異化的研發投入、供應鏈建設和商業性合作策略來重塑競爭格局。一些企業強調整合式開發管道，將製劑改進與可靠的上市後證據結合，以保持臨床優勢。另一些企業則專注於生產規模和成本效益，以在價格競爭力方面取勝，或透過非專利上市和授權許可來擴大市場准入。藥物研發企業與區域分銷商和契約製造之間的策略合作，在加速產品進入市場和確保不同地域市場的穩定供應方面，仍然發揮著至關重要的作用。

為製造商、經銷商和政策制定者提供切實可行的、優先排序的策略行動，以增強韌性、擴大患者獲取途徑並確保負責任的商業化。

行業領導者可以採取優先措施，增強韌性，擴大患者用藥管道，並調整商業性策略以適應不斷變化的臨床和監管預期。首先，多元化採購管道並投資區域製造能力，可以降低關稅波動和物流衝擊帶來的風險，同時縮短補貨週期，並確保符合區域監管要求。其次，建立強大的真實世界證據項目，將治療用途與有意義的臨床結果聯繫起來，有助於與支付方進行價值評估，並支持醫療機構將相關藥物納入藥品目錄。

對用於深入了解該治療領域的多資訊來源調查方法、數據檢驗過程和分析方法進行透明的解釋。

該分析基於透明、可重複的調查方法，整合了監管文件、臨床文獻、供應鏈資訊和相關人員訪談，從而形成一致的證據基礎。資料檢驗方法包括交叉引用公開的監管文件和製造商資訊披露，以及透過與分銷和採購專業人員的訪談來補充營運觀察。跨多個資訊來源的三角驗證降低了對任何單一資料集的依賴，並增強了對營運和策略洞察的信心。

策略要點綜述，重點闡述與沙庫巴曲Valsartan鈉片劑使用相關的利害關係人的臨床、商業和營運優先事項。

綜合研究結果凸顯了一系列策略重點，這些重點將臨床證據、商業性執行和營運韌性聯繫起來。在臨床方面，與指南驅動的治療方案保持一致，並為製劑研發人員提供可靠的真實世界療效數據，對於確保藥物在醫院和門診護理環境中的持續應用至關重要。在商業方面，將數位化藥局解決方案與傳統醫院和零售通路結合的多元化分銷模式，將有助於保障醫療服務的連續性，並滿足不斷變化的患者偏好。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 沙庫巴曲Valsartan鈉錠市場依產品類型分類

  • 品牌
  • 非專利的

9. 沙庫巴曲Valsartan鈉片市場（依規格分類）

  • 24/26mg
  • 49/51mg
  • 97/103mg

第10章 沙庫巴曲Valsartan鈉錠市場依劑型分類

  • 薄膜衣片
  • 藥片

第11章 沙庫巴曲Valsartan鈉片市場（依通路分類）

  • 離線
  • 線上

第12章 沙庫巴曲Valsartan鈉片市場（依最終用戶分類）

  • 診所
  • 居家照護
  • 醫院

第13章 沙庫巴曲Valsartan鈉錠市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 沙庫巴曲Valsartan鈉片市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國沙庫巴曲Valsartan鈉錠市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國沙庫巴曲Valsartan鈉片市場

第17章：中國沙庫巴曲Valsartan鈉片市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Labs Limited
  • Lupin Limited
  • MacLeod's Pharmaceuticals Ltd.
  • MSN Laboratories Private Limited
  • Mylan NV
  • Natco Pharma Limited
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-7A380DA7C470

The Sacubitril Valsartan Sodium Tablets Market was valued at USD 10.22 billion in 2025 and is projected to grow to USD 10.98 billion in 2026, with a CAGR of 7.78%, reaching USD 17.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.22 billion
Estimated Year [2026] USD 10.98 billion
Forecast Year [2032] USD 17.28 billion
CAGR (%) 7.78%

A concise orientation to sacubitril valsartan sodium tablets, therapeutic context, clinical relevance, and strategic considerations for stakeholders in cardiovascular care

Sacubitril valsartan sodium tablets occupy a pivotal role within contemporary heart failure management, combining neprilysin inhibition and angiotensin receptor blockade to modify disease pathways that contribute to morbidity and mortality. Clinicians increasingly rely on this combination therapy as part of guideline-directed medical care for appropriate patient populations, and its adoption sits at the intersection of clinical evidence, formulary decisions, and supply availability. For industry stakeholders, understanding clinical adoption trends, therapeutic positioning, and the operational factors that enable consistent patient access is essential for coherent strategy development.

This introduction situates the compound within therapeutic and commercial contexts without reiterating clinical trial minutiae. It emphasizes practical implications for manufacturing, regulatory affairs, distribution logistics, and payer engagement. By framing the therapy as both a clinical asset and an operational challenge, the narrative sets expectations for the subsequent sections, which explore transformative shifts in the landscape, tariff-driven supply impacts, segmentation nuances, regional dynamics, competitive positioning, and recommended strategic actions. Readers will find a balanced synthesis that aligns clinical utility with the real-world considerations that determine whether patients receive timely and sustained access to treatment.

Emerging therapeutic, regulatory, and supply dynamics reshaping the sacubitril valsartan sodium tablet landscape and influencing clinical adoption and distribution networks

The therapeutic and commercial environment for sacubitril valsartan sodium tablets is undergoing several converging shifts that are redefining how the product is developed, distributed, and reimbursed. Advances in real-world evidence generation and electronic health records are enabling clearer illustrations of patient outcomes outside controlled trials, thereby influencing formulary decisions and provider uptake. Simultaneously, regulators in multiple jurisdictions are clarifying post-approval requirements for risk management and manufacturing quality, prompting manufacturers to optimize quality systems and supply chain transparency.

Moreover, digital distribution channels and growing patient preference for pharmacy home delivery are altering traditional dispensing patterns and placing new demands on cold-chain integrity and adherence support. Payers and integrated delivery networks are placing greater emphasis on value-based contracting and outcomes-linked arrangements, which encourages manufacturers to demonstrate clear linkage between therapeutic use and measurable clinical endpoints. Taken together, these dynamics are prompting stakeholders to re-evaluate commercialization strategies, invest in strengthened real-world data programs, and pursue more collaborative relationships with health systems to ensure both clinical uptake and operational resilience.

Assessment of the cumulative implications of United States tariff changes in 2025 on supply chains, pricing pressures, and cross-border trade of sacubitril valsartan sodium tablets

Recent tariff adjustments enacted in 2025 have created complex downstream effects for the international supply chains that support pharmaceutical products, including sacubitril valsartan sodium tablets. Import duties and related administrative changes affect input sourcing decisions, manufacturing location economics, and the relative competitiveness of finished product suppliers. Manufacturers that relied on cross-border supply of active pharmaceutical ingredients or finished dosage forms have had to reassess contract terms, hedging strategies, and inventory buffers to maintain uninterrupted supply to clinical channels.

Consequently, procurement teams have increased emphasis on supplier diversification and nearshoring options to reduce exposure to tariff volatility and logistical friction. Distributors and wholesalers face altered landed-cost calculations that may necessitate contract re-pricing and renegotiation with institutional customers, while hospital systems adjust procurement timing to mitigate cost spikes. In parallel, manufacturers are evaluating strategic inventory placement and alternative trade routes to preserve distribution continuity. These collective actions illustrate how tariff shifts propagate through manufacturing, logistics, and commercial negotiations, compelling stakeholders to adopt flexible sourcing models, reinforce contract agility, and embed tariff scenario planning within broader risk management frameworks.

Deep segmentation-driven insights revealing how distribution channels, end-users, product types, strengths, and dosage forms influence access and clinical utilization

Segmentation drives a nuanced understanding of utilization pathways and access dynamics for sacubitril valsartan sodium tablets, and a granular view is essential for targeted strategy. Examining distribution channels reveals divergent operational realities: hospital pharmacies operate within government or private hospital purchasing frameworks that emphasize formulary committees and institutional contracts, online pharmacies introduce direct-to-patient fulfillment dynamics with regulatory compliance and cold-chain considerations, and retail pharmacies manifest as chain-based operations with standardized procurement alongside independent outlets that compete on local relationships and immediacy of stock.

End-user segmentation further clarifies demand signals by distinguishing clinic settings from home care delivery and hospital-based administration, each of which imposes specific requirements for packaging, patient support, and adherence monitoring. Product-type differentiation between branded and generic versions affects pricing structures, intellectual property considerations, and commercial messaging, while strength variations-24/26 mg, 49/51 mg, and 97/103 mg-demand manufacturing flexibility and inventory planning to meet prescriber preference and titration protocols. Dosage form distinctions such as film-coated tablets versus standard tablets introduce manufacturing process choices and influence patient acceptability and shelf stability. Together, these segmentation dimensions inform channel strategies, production prioritization, and patient engagement approaches that align clinical practice patterns with supply-side execution.

Regional differentiation and commercial dynamics across Americas, Europe Middle East & Africa, and Asia-Pacific informing manufacturing, regulatory, and distribution strategies

Geographic nuances shape regulatory interactions, manufacturing location decisions, and commercial deployment for sacubitril valsartan sodium tablets, and a regional lens helps prioritize capability investments. In the Americas, integrated health systems, advanced payer models, and established distribution networks create opportunities for value-based contracting and broad clinical adoption, yet they also require alignment with stringent pharmacovigilance and reimbursement documentation. Stakeholders operating in Europe, Middle East & Africa confront heterogeneity in regulatory timelines, pricing negotiation frameworks, and procurement practices, which favors adaptive market entry strategies and localized regulatory support.

Across Asia-Pacific, rapid growth in health infrastructure, an expanding base of chronic disease management programs, and active pharmaceutical manufacturing capacity present both demand potential and opportunities for regional production. However, this region also features diverse regulatory expectations and variable patient affordability dynamics that necessitate tiered commercialization approaches. In all regions, stakeholders must balance global quality standards with localized operational execution, leveraging strategic partnerships and regulatory intelligence to accelerate approvals, maintain supply continuity, and optimize distribution networks for timely patient access.

Corporate positioning and competitive behaviors of leading developers and manufacturers shaping innovation trajectories and partnership opportunities in this therapeutic class

Companies participating in this therapeutic category exhibit differentiated approaches to research investment, supply chain architecture, and commercial partnerships, shaping the competitive landscape. Some firms emphasize integrated development pathways that couple formulation enhancements with robust post-market evidence generation to sustain clinical preference. Others concentrate on manufacturing scale and cost efficiency to compete on affordability and broaden access through generic introductions or licensing arrangements. Strategic alliances between originators and regional distributors or contract manufacturers continue to be central to accelerating market entry and ensuring consistent supply in geographically diverse markets.

In addition, corporate behavior reflects varying prioritization of differentiated services such as patient support programs, digital adherence solutions, and outcome measurement platforms. These ancillary offerings increasingly influence prescriber choice and payer negotiations by demonstrating treatment value beyond clinical endpoints. Observing competitor movements in intellectual property management, global production footprints, and commercial partnerships provides actionable signals for entities seeking to position their portfolio advantageously, whether through innovation-led differentiation, cost-focused scalability, or collaborative distribution models that extend reach while protecting operational resilience.

Practical, prioritized strategic actions for manufacturers, distributors, and policymakers to enhance resilience, patient access, and responsible commercialization

Industry leaders can implement prioritized actions that strengthen resilience, expand patient access, and align commercial approaches with evolving clinical and regulatory expectations. First, investing in diversified sourcing and regional manufacturing capacity reduces exposure to tariff disruptions and logistics shocks, while concurrently shortening replenishment cycles and supporting localized regulatory compliance. Second, building robust real-world evidence programs that link therapeutic use to meaningful clinical outcomes enables value-based discussions with payers and supports formulary inclusion across institutional settings.

Third, enhancing distribution strategies to incorporate digital pharmacy channels, direct-to-patient delivery, and strengthened hospital pharmacy integration will improve adherence and reduce interruptions in therapy. Fourth, adopting flexible pricing strategies and risk-sharing arrangements can expedite access while aligning incentives across payers, providers, and manufacturers. Finally, expanding patient support services and digital adherence tools complements clinical therapy by addressing persistence and tolerability concerns. Executing these recommendations requires cross-functional alignment between R&D, manufacturing, commercial, and regulatory teams, with leadership commitment to measurable milestones and continuous improvement based on stakeholder feedback.

Transparent explanation of multi-source research methodology, data validation practices, and analytic approaches used to produce robust insights on this therapy class

The analysis draws on a transparent and reproducible methodology that synthesizes regulatory documents, clinical literature, supply chain intelligence, and stakeholder interviews to form a coherent evidence base. Data validation practices included cross-referencing public regulatory filings with manufacturer disclosures and corroborating operational observations through interviews with distribution and procurement professionals. Triangulation across sources reduced reliance on any single dataset and enhanced confidence in operational and strategic findings.

Analytic approaches combined qualitative synthesis with scenario-based supply chain stress testing and comparative review of regulatory frameworks across major regions. The methodology emphasized traceability of conclusions to source material, rigorous review cycles, and subject matter expert validation to ensure that insights reflected both documented facts and practical realities encountered by health systems and commercial partners. Where appropriate, sensitivity analyses examined alternative operational responses to tariff and supply disruptions, enabling readers to appreciate plausible strategic pathways and the prerequisites for successful implementation.

Synthesis of strategic takeaways emphasizing clinical, commercial, and operational priorities for stakeholders engaged with sacubitril valsartan sodium tablet utilization

The synthesis of findings underscores a set of strategic priorities that bridge clinical evidence, commercial execution, and operational resilience. Clinically, maintaining alignment with guideline-directed therapy and ensuring prescribers have access to robust real-world outcomes data will be decisive in securing sustained utilization within hospital and ambulatory settings. Commercially, diversified distribution approaches that integrate digital pharmacy solutions with traditional hospital and retail pathways support continuity of care and meet evolving patient preferences.

Operational priorities include strategic sourcing and inventory practices to mitigate tariff and logistics volatility, as well as investment in manufacturing flexibility to accommodate strength and dosage-form variations. Corporate strategies that pair differentiated clinical services with cost-efficient production models will be best positioned to navigate payer scrutiny and institutional contracting. In summary, stakeholders that proactively integrate evidence generation, supply chain resilience, and patient-centered distribution mechanisms will optimize both clinical impact and commercial performance in a dynamic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sacubitril Valsartan Sodium Tablets Market, by Product Type

  • 8.1. Branded
  • 8.2. Generic

9. Sacubitril Valsartan Sodium Tablets Market, by Strength

  • 9.1. 24/26 mg
  • 9.2. 49/51 mg
  • 9.3. 97/103 mg

10. Sacubitril Valsartan Sodium Tablets Market, by Dosage Form

  • 10.1. Film-Coated Tablet
  • 10.2. Tablet

11. Sacubitril Valsartan Sodium Tablets Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Sacubitril Valsartan Sodium Tablets Market, by End-User

  • 12.1. Clinic
  • 12.2. Home Care
  • 12.3. Hospital

13. Sacubitril Valsartan Sodium Tablets Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Sacubitril Valsartan Sodium Tablets Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Sacubitril Valsartan Sodium Tablets Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Sacubitril Valsartan Sodium Tablets Market

17. China Sacubitril Valsartan Sodium Tablets Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aspen Pharmacare Holdings Limited
  • 18.6. Aurobindo Pharma Limited
  • 18.7. Cipla Limited
  • 18.8. Dr. Reddy's Laboratories Ltd.
  • 18.9. Glenmark Pharmaceuticals Ltd.
  • 18.10. Hetero Labs Limited
  • 18.11. Lupin Limited
  • 18.12. MacLeod's Pharmaceuticals Ltd.
  • 18.13. MSN Laboratories Private Limited
  • 18.14. Mylan N.V.
  • 18.15. Natco Pharma Limited
  • 18.16. Novartis AG
  • 18.17. Orion Corporation
  • 18.18. Pfizer Inc.
  • 18.19. Sandoz International GmbH
  • 18.20. Sun Pharmaceutical Industries Ltd.
  • 18.21. Teva Pharmaceutical Industries Ltd.
  • 18.22. Torrent Pharmaceuticals Ltd.
  • 18.23. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 24/26 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 24/26 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 24/26 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 49/51 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 49/51 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 49/51 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 97/103 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 97/103 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY 97/103 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY FILM-COATED TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY FILM-COATED TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY FILM-COATED TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 99. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 102. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 103. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GCC SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 120. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 121. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. G7 SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 126. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 127. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NATO SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA SACUBITRIL VALSARTAN SODIUM TABLETS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)